MinorSodium-glucose co-transporter 2 inhibitors (SGLT2i)×Fixed-dose combination: DPP-4 inhibitor plus biguanide
Updated · Methodology
Mechanism
Metformin is excreted unchanged by the kidneys, so it accumulates when renal function worsens acutely and the risk of lactic acidosis rises. When drugs that can adversely affect renal function are started together with metformin, renal function is monitored closely (vildagliptin/metformin SmPC, European Medicines Agency, EMA). Empagliflozin removes glucose in the urine, and the accompanying osmotic diuresis can moderately lower blood pressure. At the start of treatment, estimated glomerular filtration rate (eGFR) falls slightly, by a mean of 3 mL/min/1.73 m², which is attributed to acute haemodynamic changes (empagliflozin SmPC, EMA). According to the US label, empagliflozin can cause intravascular volume depletion, sometimes with symptomatic hypotension or acute transient changes in creatinine. Acute kidney injury has been reported after marketing (Jardiance label, US Food and Drug Administration, FDA). The pharmacokinetics of empagliflozin and metformin do not change significantly when they are taken together (empagliflozin/metformin SmPC, EMA). Empagliflozin and vildagliptin share no metabolic pathway: empagliflozin is metabolised by UGT enzymes, while vildagliptin is hydrolysed without cytochrome P450 involvement (empagliflozin and vildagliptin/metformin SmPCs, EMA).
Symptoms
The documents describe no symptoms specific to this combination. Empagliflozin can cause volume depletion with a fall in blood pressure, more often in people aged 75 years or older. It can also cause genital and urinary tract infections and ketoacidosis, including with blood glucose below 14 mmol/L (empagliflozin SmPC, European Medicines Agency, EMA). A very rare but serious complication of metformin is lactic acidosis, with acidotic breathlessness, abdominal pain, muscle cramps, weakness and hypothermia, followed by coma. Vildagliptin is associated with a risk of acute pancreatitis (vildagliptin/metformin SmPC, EMA). When empagliflozin was added to metformin, or to linagliptin (another dipeptidyl peptidase-4, DPP-4, inhibitor) plus metformin, hypoglycaemia was as frequent as with placebo (empagliflozin SmPC, EMA).
Management
According to the documents, the combination is acceptable, and the doses need no change. Both drugs are used together with other glucose-lowering medicines (empagliflozin and vildagliptin/metformin SmPCs, European Medicines Agency, EMA), and the pharmacokinetics of empagliflozin and metformin do not change significantly when they are taken together (empagliflozin/metformin SmPC, EMA). As a general rule for metformin, drugs that can adversely affect renal function are started with caution, and renal function is monitored closely (vildagliptin/metformin SmPC, EMA). After empagliflozin starts, signs of volume depletion and renal function are monitored (Jardiance label, US Food and Drug Administration, FDA). Glomerular filtration rate (GFR) is assessed before metformin starts and at least once a year after that. In older people and in those at risk of worsening renal function, it is assessed every 3–6 months. Metformin is contraindicated when GFR is below 30 mL/min (vildagliptin/metformin SmPC, EMA). Renal function is also checked before empagliflozin starts and at least once a year after that (empagliflozin SmPC, EMA). Volume status is assessed before the start, and any depletion is corrected first (Jardiance label, FDA). In dehydration from severe vomiting, diarrhoea, fever or low fluid intake, metformin is stopped temporarily (vildagliptin/metformin SmPC, EMA). With fluid loss, a temporary interruption of empagliflozin is considered until the loss is corrected (empagliflozin SmPC, EMA). Empagliflozin is interrupted in people hospitalised for major surgery or serious acute illness (empagliflozin SmPC, EMA). Metformin is stopped at the time of surgery under general, spinal or epidural anaesthesia and restarted after 48 hours or once oral feeding resumes, provided renal function is stable (vildagliptin/metformin SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Empagliflozina (EU/1/14/930), sección 4.5 (2026)– EMA, Jardiance 10 mg comprimidos recubiertos con película (Boehringer Ingelheim International GmbH, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114930014, consultada 30.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5 y 5.2
- FDA: Jardiance (empagliflozin) prescribing information (2026)– FDA, DailyMed setid faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 (Boehringer Ingelheim Pharmaceuticals), revisión 01/2026 (versión 31), secciones 2.3, 7 (Table 4) y 12.3
- EMA: Ficha técnica: Vildagliptina/metformina (EU/1/07/425), sección 4.5 (2026)– EMA, Eucreas 50 mg/1000 mg comprimidos recubiertos con película (Novartis Europharm Limited, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 07425009, consultada 03.11.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- EMA: Ficha técnica: Empagliflozina/metformina (EU/1/15/1003), sección 4.5 (2026)– EMA, Synjardy 5 mg/1000 mg comprimidos recubiertos con película (Boehringer Ingelheim International GmbH, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151003014, consultada 03.11.2026, sin fecha de revisión en CIMA, secciones 4.1, 4.2, 4.4 y 4.5